Amgen (AMGN) News Today

Amgen Inc. (NASDAQ: AMGN) shares recently increased and outperformed the broader market, helped by favorable analyst commentary and a higher valuation estimate. However, the stock remains below its 50-day moving average, reflecting ongoing concerns about pipeline execution, competition and patent exposure.

• Positive Sentiment: UBS initiated or reiterated a Buy rating on Amgen, providing a positive signal about the company’s valuation and commercial outlook. Amgen (AMGN) Gets a Buy from UBS
• Positive Sentiment: An updated analyst model raised Amgen’s fair-value estimate to US$388.03 from US$371.93. Analysts cited strong commercial execution, although they remain divided over patent risks and the company’s development pipeline. Amgen Stock Sees Modest Fair Value Lift
• Positive Sentiment: Amgen’s recent trading-session performance surpassed market returns, suggesting continued investor support despite longer-term uncertainty. The company also recently reported earnings and revenue above analyst expectations, supporting its fundamental backdrop. Amgen Surpasses Market Returns
• Positive Sentiment: Amgen is advancing a Phase 3 trial of romiplostim with prednisone for first-line immune thrombocytopenia treatment. Success could expand the drug’s addressable market and add support to the pipeline. Amgen Targets First-Line ITP Market
• Neutral Sentiment: Barclays maintained a Hold rating, while Citi reaffirmed a Hold rating and a $405 price target. The ratings indicate that analysts see upside potential but believe near-term risks are broadly balanced. Barclays Sticks to Its Hold Rating
• Negative Sentiment: Bristol Myers Squibb and Ono Pharmaceutical sued Amgen to block its proposed Opdivo biosimilar, creating potential legal costs, launch delays and commercial uncertainty. BMS and Ono Sue Amgen
• Negative Sentiment: Novartis’ failed cholesterol-drug trial increases pressure on Amgen’s olpasiran program to prove that lowering lipoprotein(a) reduces cardiovascular events. A disappointing outcome could weigh on future growth expectations. Failed Cholesterol Drug Raises the Stakes